Atlas Trials

A Phase 1b Study of Sevacizumab in Combination With Chemotherapy in Chinese Patients With Platinum-Resistant Recurrent Ovarian Cancer.

Clinical trial NCT03763123 · UNKNOWN

Trial details

NCT number
NCT03763123
Sponsor
Jiangsu Simcere Pharmaceutical Co., Ltd.
Status
UNKNOWN
Phase
Phase 1
Study type
INTERVENTIONAL
Ovarian Cancer
Start date
2018-04-24
Primary completion
2019-12-31
Enrollment
48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.